Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSJ117 24-week extension safety study in adults with moderate to severe asthma
2020-002341-42Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2021
- Modality
- Fab Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing CSJ117 plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Treatment-emergent adverse events and serious adverse events. Started Aug 2021; status: completed.
02
Drugs
ecleralimab
03
Conditions
asthma
Beyond the preview
Go deeper on 2020-002341-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002341-42.